Acadia Pharmaceuticals Inc ACAD
We take great care to ensure that the data presented and summarized in this overview for ACADIA PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACAD
View all-
Baker Bros. Advisors LP New York, NY42.9MShares$1.09 Billion9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$388 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$307 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$229 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$157 Million0.01% of portfolio
-
Morgan Stanley New York, NY4.11MShares$105 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.17MShares$80.7 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA3.02MShares$77 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.01MShares$76.7 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA2.56MShares$65.2 Million12.51% of portfolio
Latest Institutional Activity in ACAD
Top Purchases
Top Sells
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Transactions at ACAD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 18
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,000
-35.41%
|
$550,000
$25.18 P/Share
|
|
Jun 04
2025
|
Laura Brege |
SELL
Open market or private sale
|
Direct |
14,446
-48.9%
|
$303,366
$21.78 P/Share
|
|
May 29
2025
|
Laura Brege |
BUY
Exercise of conversion of derivative security
|
Direct |
9,387
+24.11%
|
-
|
|
May 29
2025
|
James M Daly |
BUY
Exercise of conversion of derivative security
|
Direct |
9,387
+21.62%
|
-
|
|
May 29
2025
|
Elizabeth A. Garofalo |
BUY
Exercise of conversion of derivative security
|
Direct |
9,387
+25.81%
|
-
|
|
May 29
2025
|
Edmund Harrigan |
BUY
Exercise of conversion of derivative security
|
Direct |
9,387
+21.13%
|
-
|
|
May 29
2025
|
Adora Ndu |
BUY
Exercise of conversion of derivative security
|
Direct |
9,387
+27.46%
|
-
|
|
May 29
2025
|
Daniel B Soland |
BUY
Exercise of conversion of derivative security
|
Direct |
9,387
+17.57%
|
-
|
|
May 29
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
32,428
+0.24%
|
-
|
|
May 16
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,000
-3.12%
|
$50,000
$25.0 P/Share
|
|
May 16
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
4,000
-8.56%
|
$88,000
$22.5 P/Share
|
|
May 02
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,327
-5.34%
|
$18,578
$14.6 P/Share
|
|
May 02
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,498
-5.28%
|
$48,972
$14.6 P/Share
|
|
May 01
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,596
+9.46%
|
-
|
|
May 01
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,815
+9.32%
|
-
|
|
Apr 08
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,708
-4.36%
|
$37,912
$14.82 P/Share
|
|
Apr 08
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,028
-4.41%
|
$14,392
$14.82 P/Share
|
|
Apr 05
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,275
+7.82%
|
-
|
|
Apr 05
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+7.95%
|
-
|
|
Mar 26
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,095
-4.89%
|
$18,615
$17.05 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 32.4K shares |
|---|---|
| Exercise of conversion of derivative security | 135K shares |
| Open market or private sale | 86.1K shares |
|---|